Louis Lehot’s Comments from Recent NACD Webinar Highlighted in Fortune Newsletter
28 April 2023
Foley & Lardner LLP Partner Louis Lehot’s comments from a recent National Association of Corporate Directors webinar titled “Implications of the SVB Collapse for All Board Members,” are highlighted in Fortune’s The Modern Board newsletter.
The webinar provided board members an opportunity to reflect on both the clear and the less obvious governance and risk issues surrounding the recent banking failures and learn lessons which can be applied to every board, regardless of industry.
“It has become part and parcel of being a public company director that you will likely, at some point in the lifecycle of a company, get sued,” Lehot commented.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”